STAGE IV ESOPHAGEAL CANCER AJCC V7
Clinical trials for STAGE IV ESOPHAGEAL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV ESOPHAGEAL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV ESOPHAGEAL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo shows promise for tough esophageal cancer
Disease control OngoingThis study tested whether adding the experimental drug cixutumumab to standard chemotherapy (paclitaxel) helps people with advanced esophageal or stomach-junction cancer that has spread. About 94 adults whose cancer returned after first treatment took part. The goal was to see if…
Matched conditions: STAGE IV ESOPHAGEAL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New drug combo aims to boost Radiation's punch against tough GI cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The drug is designed to make tumor cells more sensitive to radiation therapy. Researchers aim to find the safest dose and see how well the…
Matched conditions: STAGE IV ESOPHAGEAL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 01, 2026 16:01 UTC